Objectives: On July 13, 2011, the US Food and Drug Administration (FDA) released a public health notification with concerns regarding vaginal mesh for the treatment of pelvic organ prolapse. Our study compares the frequency and type of mesh complications related to female pelvic floor disorders presenting to our center before and after this notification.
W hen considering the use of mesh to augment surgical repair of pelvic floor disorders, the therapy should improve surgical outcomes while maintaining patient safety. Synthetic mesh is commonly used in the treatment of pelvic organ prolapse and stress urinary incontinence. The use of macroporous, monofilament mesh in midurethral slings provides high continence rates, with few complications attributable to the implant. 1Y3 Similarly, type I mesh for abdominal sacral colpopexy provides an excellent long-term anatomic repair with a low complication profile, 4Y7 although long-term data from the Colpopexy and Urinary Reduction Efforts trial indicate a higher vaginal mesh erosion rate than was once thought. 8 The benefits of vaginal mesh for the repair of pelvic organ prolapse are less established. Anterior vaginal mesh may decrease anatomic recurrences 9Y11 ; however, mesh erosion rates are known to be higher when used vaginally, along with other, sometimes severe and life-altering complications, including dyspareunia, urinary incontinence, and voiding dysfunction. 11, 12 On July 13, 2011, the US Food and Drug Administration (FDA) delivered a safety communication regarding the use of transvaginal mesh for pelvic organ prolapse repair. 13 The update explains that mesh augmentation may provide an anatomic benefit when compared to traditional repair; however, it also highlights that serious complications associated with vaginal mesh were not rare.
The FDA public safety message attempts to improve public and provider awareness on the potential complications of vaginal mesh use. However, it remains unclear whether the FDA warning has affected outpatient evaluation of mesh complications or increased the number of complications being detected. This is important, as the full public health impact of these complications is still being determined. The purpose of this study was to compare the frequency and type of mesh complications presenting to our tertiary Female Pelvic Medicine and Reconstructive Surgery clinic before and after the 2011 FDA notification. We also investigated preY and postYFDA notification differences in patient-perceived versus provider-diagnosed mesh complications.
MATERIALS AND METHODS
The Vanderbilt University Institutional Review Board approved our retrospective cohort study. We compared all mesh complications in the 12 months preceding the July 13, 2011 FDA mesh notification and all mesh complications in the 6 months that followed. We chose a 12-month period for the preYFDA notification group to avoid any seasonal bias in the comparison group. Inclusion criteria were all Female Pelvic Medicine and Reconstructive Surgery consults and new patient visits from July 1, 2010 to January 13, 2012, as identified by current procedural terminology (CPT) codes 99201-99205 and 99241-99245. Each electronic medical record was manually reviewed and data extracted into a RedCap database (Research Electronic Data Capture).
14 Each chart was reviewed for demographic information, presenting chief complaint, provider diagnosis after complete workup, and a history of prior mesh placement for pelvic floor disorders. We defined mesh as any biologic or synthetic graft used for the treatment of pelvic organ prolapse or urinary incontinence. Although the focus of the FDA notification was on vaginal mesh procedures, we included complications from all mesh procedures, including midurethral slings, sacral colpopexies, and biologic grafts, as patients may not be aware of the differences between these procedures. The evaluating physician made the final decision regarding whether a complication was the result of a mesh graft. For women with a mesh complication, physical examinations, urodynamic evaluations, operative findings, and patient symptoms were also reviewed. Because recurrent prolapse and urinary incontinence can occur after any pelvic reconstructive surgery, these were not considered mesh complications for the purposes of this study.
Mesh complications were classified using the 2011 IUGA/ ICS guidelines. 15 The IUGA/ICS classification system has objective categories of mesh complications (no mesh exposure, mesh exposure e1 cm, mesh exposure 91 cm, urinary tract compromise, rectal or bowel compromise, skin or musculoskeletal), which are divided into divisions (asymptomatic, symptomatic, and infection) and then subclassified (asymptomatic, symptomatic with provoked pain, symptomatic with intercourse, symptomatic with pain during activity, and spontaneous pain). Thus, an individual patient may have multiple IUGA/ICS mesh complications for a single category of complication. When analyzing the frequency of these complications, the denominator was the total number of mesh complications for a given time period, not the total number of patients. A separate analysis was performed in which women were classified into clinically pertinent categories: vaginal exposure, pain, erosion into bowel, bladder outlet obstruction, vesicovaginal fistula, sinus tract formation (cutaneous or vaginal to sacrum), or neurologic sequelae. This simplified the analysis, as an individual could have multiple types of mesh complications, but not multiple complications within the same category (unlike the IUGA/ ICS system). This allowed the denominator for frequency calculations to be the total number of patients.
Our primary aim was to compare the percentage of new patients presenting with a mesh complication before and after the FDA notification. Secondary aims were to compare prenotification and post-notification differences in the following: (1) patient-perceived mesh complications, (2) provider-diagnosed complications, and (3) in the category, time, and location of mesh complications using the 2011 IUGA/ICS guidelines.
Continuous variables with a symmetric distribution were summarized using the mean and standard deviation, and continuous variables with a skewed distribution were summarized using the median, and the 25th and 75th percentiles. Continuous variables were compared using the Wilcoxon rank sum test. Categorical variables were summarized using percentages. The Pearson W2 test and the Fisher exact test were used to compare categorical variables before and after the FDA notification. We used the Pearson test if the sample size was sufficiently large and the Fisher test in cases of small sample size. In particular, the sample size was judged to be small if 2 or more expected cell totals from the contingency table were less than 5. Results are summarized using 95% confidence intervals or P values. All analyses were conducted using the R statistics program (version 2.14.2).
RESULTS
We identified 878 women in the 12 months before the FDA notification and 489 women in the 6 months after the FDA notification who presented as new patients to our Female Pelvic Medicine and Reconstructive Surgery clinic. Age, parity, race, and body mass index were similar for the 2 time periods. Of white patients, a higher percentage was identified as not Hispanic or Latino after the FDA notification (and fewer were categorized as unknown), reflecting a change in how ethnicity was recorded in patients' charts at the time of the FDA notification (Table 1 ). There was a 1.7-fold increase in the percentage of new patients with prior mesh placement after the FDA notification (12% before vs 20% after notification; P G 0.001; Table 1 ) of these, 31.2% and 45.9% presented with a patient-perceived mesh complication, respectively (difference, 14.7%; 95% confidence interval [CI], 1.6%Y27.9%; Table 2 ). The data were inconclusive regarding any difference in provider-diagnosed mesh complications between the two periods (difference, 5.3%; 95% CI, j8.1% to 18.8%; Table 2 ). Seventy-six percent (26/34) of women presenting with a mesh complaint had a diagnosis of mesh complication before the FDA notification, and 64% (29/45) of women presenting with a mesh complaint had a diagnosis of mesh complication after the notification. Of women with pelvic mesh, the most common types were vaginal mesh for prolapse and midurethral slings ( Table 2) . Vaginal mesh for prolapse was more prevalent before the FDA notification in our population (53% before vs 39% after; difference of 14% [95% CI, 0%Y29%], Table 2 ). Complication types were similar between the 2 time periods, with vaginal mesh exposure, pain, and bladder outlet obstruction being the most common complications (Table 2) . Of note, all mesh complications were due to permanent synthetic mesh; none were the result of a biologic graft. Biologic grafts were present in 22.9% (25/109) of women with a history of mesh in the preY FDA notification period and 16.3% (16/98) of women with prior mesh in the postYFDA notification period. Two percent (5/207) of women with a prior graft had only biologic graft placed, whereas 17.3% (36/207) of women with a prior graft had a combination of biologic graft and permanent mesh.
When using the IUGA/ICS classification system, women could be categorized as having multiple mesh complications of the same type. There were 52 complications seen in 42 women before the FDA notification and 57 complications in 43 women after the notification. The category and site of complications were similar between the 2 groups. Of the complications seen, a fifth were bladder outlet obstruction: 23% (12/52) before the FDA notification and 21% (12/57) after the FDA notification. Most of these were after a midurethral sling (8 vs 10, respectively), minisling (2 vs 1) or pubovaginal sling (1 vs 1). One bladder outlet obstruction was seen after an anterior vaginal mesh kit. These, along with one vesicovaginal fistula, were coded as IUGA/ICS category 4B complications (lower urinary tract injury or compromise). In addition, we saw more delayed diagnoses of mesh complications (T4 defined as 912 months from the time of mesh placement) after the FDA notification, 52% vs 79%, respectively (difference, 27%; 95% CI, 10%Y44%; Table 3 ).
The types of complications seen after a specific mesh procedure were similar before and after the FDA notification ( Table 2 ). The following data refer to total complications after specific mesh procedures. Forty-five percent (43/96) of patients with vaginal mesh were found to have a complication over the entire time period of this study. Although the FDA warning focused only on vaginal mesh, we saw complications in more than a third of women with a prior sacral colpopexy (35% [6/17] ); two of these involved products other than type I monofilament mesh (Gortex and Mersilene). Additionally, 30% (33/109) of mesh complications were related to a midurethral sling and presented as bladder outlet obstruction, vaginal exposure, and/or pain. Bladder outlet obstruction was seen in 14% (18/128) of women with a prior transobturator or retropubic midurethral sling and in 20% (3/15) of women after a minisling; P = NS. These reflect complication rates among women seeking tertiary level urogynecologic care and are not complication rates after these procedures, as the total number of procedures is not known.
DISCUSSION
After the FDA mesh notification, we saw increases in the percentage of new patients with prior mesh placement and in the rate of mesh complaints among these patients. Complications were not limited to transvaginal mesh, and an unexpectedly high proportion of the complications were related to sacral colpopexy and midurethral sling procedures. Strengths of our study include the large sample size and catchment capacity of our tertiary care center. The sparse density of tertiary academic medical centers in the southeastern United States results in women from a large geographic region presenting to our center, with travel distances of greater than 200 miles frequently seen. The use of 2 mesh classification and comparison techniques allowed us to report on a variety of complications in a comprehensive manner. Additionally, we are not aware of any other studies that specifically compare patient-perceived mesh complications with provider-diagnosed complications.
Limitations of our study include the lack of a denominator for the number of mesh procedures performed in our geographic region. Therefore, the reported complication rates are only representative of the referrals seen at our institution. Second, there is the potential for selection bias owing to reporting solely from a referral base, especially given our role as a tertiary care center that frequently manages surgical failures and mesh complications. Acute postoperative complications, such as acute blood loss and bowel obstruction, may have been evaluated and treated at other facilities closer to the location of the primary surgery and were not reported in this study. The IUGA/ICS mesh complication classification was used retrospectively; and as such, there may be underreporting of some complications. Of note, the IUGA/ICS classification system was introduced after the initial referral visit for many of our preYFDA notification patients. Another potential limitation was that the postY FDA notification period was defined as a 6-month period, and it is unclear if this is sufficient time to see the full impact of the FDA notification on the public and providers. Lastly, defining mesh as both synthetic and biologic is another potential disadvantage, as these implants likely have different complication rates; however, our main goal was to completely capture all mesh complications. No complications were identified after a biologic graft. The IUGA/ICS classification system allowed us to systematically and comprehensively identify a wide range of complications; however, the numerous subcategories limited analysis of the data. The strength of this classification scheme is in documenting the vast array of potential complications. Unfortunately, it does not lend itself to meaningful clinical or statistical analysis, as seen when viewing the rather cumbersome data in Table 3 . The numerous subcategories reduced our statistical power to address specific mesh complications. The classification system also does not account for complication acuity. Additionally, despite being the most comprehensive classification system available, the IUGA/ICS system has significant potential for classification bias. Recent studies have shown poor interrater reliability when using the IUGA/ICS classification system. 16, 17 A simplified classification system cognizant of the needs of both the physician and the researcher would be beneficial.
We hypothesize that the increase in patient-perceived mesh complications is due to better public/provider awareness secondary to the FDA notification. However, other factors such as television commercials and class action lawsuits may also play a role and, without knowing the number of implanted mesh products, we are unable to determine if there was a change in the number of mesh implants during the study period. Interestingly, women with a mesh complication diagnosed in the post-FDA notification period were more likely to have had their mesh placed greater than 12 months earlier, illustrating that most of the complications diagnosed in this period were a result of mesh placed before the FDA notification. This suggests that more women are aware of the potential for mesh complications and are seeking further evaluation. Future investigations are warranted to determine the means by which patients are made aware of this information.
The July 13, 2011 FDA mesh notification brought to light safety concerns for the use of vaginal mesh for the repair of pelvic organ prolapse. The notification did not comment specifically on the safety of using mesh for the treatment of stress urinary incontinence. The multicenter Trial of Midurethral Slings revealed a mesh complication rate, defined as erosions and exposures, of 4% after 2 years from the initial surgery. 1 Their study also found a rate of voiding dysfunction between 1.8% and 8.2% depending on the type of midurethral sling and whether a concomitant pelvic floor procedure was performed. Currently, the FDA is investigating the efficacy and safety of sling procedures in the treatment of stress urinary incontinence.
Skala et al 18 retrospectively used the IUGA/ICS classification system to report on 179 patients with a mesh complication over a 6-year period. Of these patients, 125 women had a previous sling procedure for incontinence and 54 women had vaginal mesh placement for prolapse repair. Of the complications after a midurethral mesh sling, 44.8% (56/125) were found to have bladder outlet obstruction. Of all the complications for vaginal mesh, 55.5% (30/54) had a vaginal mesh exposure. In our study, although no difference in sling complication rates was found between the 2 periods, a high overall rate of bladder outlet obstruction was likewise observed. Similarly, a high complication rate was noted with sacral colpopexies; however, a relatively low number of patients who underwent sacral colpopexy were evaluated (n = 17). The main weakness of their study and our own is the lack of a denominator regarding the number of mesh procedures for pelvic floor disorders.
In conclusion, more women presented with a patientperceived mesh complication after the FDA notification, but the actual frequency, type, and location of mesh complications did not change in our referral-based population. A surprisingly high percentage of the complications were due to sacral colpopexy and midurethral sling procedures, neither of which was the focus of the 2011 FDA notification. These observations are helpful for physicians taking care of women with a history of pelvic mesh and highlight the frequency of these issues presenting to tertiary care centers.
